<DOC>
	<DOCNO>NCT02784912</DOCNO>
	<brief_summary>Prevalence HF reach 1-2 % developed population , consequently significant problem become frequent occurrence ventricular arrhythmia ( VA ) - sustain ventricular tachycardia ( sVT ) electrical storm ( ES ) require radiofrequency ablation . The aim study create model risk stratification identify patient increase risk occurrence composite ( cardiovascular death rehospitalization , arrhythmia recurrence ) secondary ( inadequate device therapy , all-cause death rehospitalization , intensification atrial arrhythmia ) endpoints ablation ES sustain VT. Model base additional measurement N-terminal pro brain natriuretic peptide ( NT-proBNP ) , Galectin-3 , suppressor tumorigenicity 2 ( ST2 ) , high sensitive troponin T ( hs-TnT ) , high sensitive C-reactive protein ( hs-CRP ) , iron deficiency clinical- , electrocardiographic- echocardiographic assessment .</brief_summary>
	<brief_title>Biomarkers Risk Stratification Sustainted Ventricular Tachycardia Electrical Storm After Ablation</brief_title>
	<detailed_description>Patients ischemic heart failure ( HF ) reduce left ventricle ejection fraction high risk recurrence VA , ultimately leading death . Such patient often require ablation . On hand , ablation VA patient post-infarction scar technically difficult procedure often associate short-term efficacy . Risk factor recurrence VA difficult identify , although mention e.g . reduce leave ventricular ejection fraction , exacerbation chronic HF electrolyte abnormality . VA trigger ongoing inflammation fibrosis , reflect level biomarkers . Thus , worth search biomarkers increase possibility effective stratification risk arrhythmia recurrence patient undergoing ablation sVT ES . The hypothesis study biomarker-related risk stratification may beneficial patient ES sVT . Sample size assessment make specify number participant necessary demonstrate effect . The study include least 50 patient ( meet inclusion/exclusion criterion ) ischemic heart failure , reduce leave ventricle ejection fraction admit hospital qualified ablation due ES sVT . For every patient provide case report form ( CRFs ) include clinical status admission discharge , laboratory finding , management index hospitalization , data ablation procedure , pharmacotherapy , well in-hospital one-year outcome . Serum collect ablation 1-month discharge hospital biomarkers measurement . Patients tele-monitored â‰¥12-months . There carried two control visit ( include assessment clinical , echocardiographic , electrocardiographic Holter-ECG parameter ) 1- 3 month discharge .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<mesh_term>Tachycardia , Ventricular</mesh_term>
	<criteria>Inclusion Criteria ( require ) : &gt; = 18 year sign consent ischemic heart disease leave ventricle ejection fraction &lt; = 35 % admission hospital due electrical storm sustain ventricular tachycardia qualification ablation arrhythmia patient already implant cardioverter defibrillator ( ICD ) / cardiac resynchronization therapy defibrillator ( CRTD ) patient qualified implantation nonischemic heart disease current ischemia potentially reversible cause ( e.g . electrolyte abnormality , drug intoxication ) arrhythmia congenital genetic heart disease serious comorbidities ( e.g . neoplasm ) chronic inflammatory disease ( e.g . inflammatory bowel disease , rheumatoid arthritis ) renal failure ( creatinine &gt; 2,5 mg/dl )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Biomarkers</keyword>
	<keyword>Ventricular Dysfunction</keyword>
	<keyword>Ventricular Tachycardia</keyword>
	<keyword>Electrical Storm</keyword>
	<keyword>ST2</keyword>
	<keyword>Galectin-3</keyword>
	<keyword>NT-proBNP</keyword>
	<keyword>Iron Deficiency</keyword>
	<keyword>hs-CRP</keyword>
	<keyword>hs-TnT</keyword>
</DOC>